![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
"Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt – results from the GUARD study. Curr Med Res Opin 2017;33:797-801." Current Medical Research and Opinion, 33(12), pp. 2261–2262
Transparency
Declaration of funding
This letter was written independently; no company or institution supported the authors financially or by providing a professional writer.
Declaration of financial/other relationships
N.K. has disclosed that she has given talks, attended conferences and participated in trials sponsored by Amgen, Angelini, AstraZeneca, Boehringer Ingelheim, MSD, Novartis, Novo Nordisk, Sanofi and WinMedica. V.G.A. has disclosed that he has given talks, attended conferences and participated in trials sponsored by MSD, Angelini, Sanofi, and Amgen. A.K. has disclosed that he has given talks and attended conferences sponsored by AstraZeneca, Novartis and WinMedica.
CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.